Noxopharm Ltd. has released a press release.
Noxopharm raises $5.5 million to advance clinical program
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- Suspension from Official Quotation
- Noxopharm provides update on NOX66 Clinical Trial Program
- Idronoxil data provides hope to treat secondary brain cancer
- NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment
- St Vincents Cancer Study to Commence-NOX66 and Radiotherapy
Later from Noxopharm
- Reinstatement to Official Quotation
- Important Brain Cancer Findings for NOX66 Program
- Positive Clinical Outcomes for NOX66 at ESMO Conference
- Establishment of Nyrada Inc.
- Australian NOX66 - Radiotherapy Study Opens
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm